secwatch / observer
8-K filed August 15, 2022, 7:59 PM ET ticker BGLC CIK 0001737523
leadership confidence high sentiment neutral materiality 0.75

Bionexus Gene Lab replaces Chairman, CEO, and President in leadership reshuffle

BioNexus Gene Lab Corp

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Soo Kow Lai

Chairman
BGLC · BioNexus Gene Lab Corp
Effective
2022-08-12
Successor
Yeat Min Fong
Filed
August 15, 2022, 7:59 PM ET
On August 9, 2022, Mr. Soo Kow Lai, the Chairman and director, Mr. Chan Chong Wong, the Chief Executive Officer and director, and Mr. Chi Yuen Leong, the President and director, notified Bionexus Gene Lab Corp (“the Company”) their desire to resign from their positions at the Company.
Appointed

Yee Meng Wong

President
BGLC · BioNexus Gene Lab Corp
Effective
2022-08-09
Filed
August 15, 2022, 7:59 PM ET
On August 9, 2022, the Board of Directors of the Company approved the appointments of Mr. Yeat Min Fong as the Chairman and director, Mr. Sook Keng Yeoh as the Chief Executive Officer and director, and Ms. Yee Meng Wong as the President and director, effective August 9, 2022.
Departed

Chan Chong Wong

Chief Executive Officer
BGLC · BioNexus Gene Lab Corp
Effective
2022-08-12
Successor
Sook Keng Yeoh
Filed
August 15, 2022, 7:59 PM ET
On August 9, 2022, Mr. Soo Kow Lai, the Chairman and director, Mr. Chan Chong Wong, the Chief Executive Officer and director, and Mr. Chi Yuen Leong, the President and director, notified Bionexus Gene Lab Corp (“the Company”) their desire to resign from their positions at the Company.
Departed

Chi Yuen Leong

President
BGLC · BioNexus Gene Lab Corp
Effective
2022-08-12
Successor
Yee Meng Wong
Filed
August 15, 2022, 7:59 PM ET
On August 9, 2022, Mr. Soo Kow Lai, the Chairman and director, Mr. Chan Chong Wong, the Chief Executive Officer and director, and Mr. Chi Yuen Leong, the President and director, notified Bionexus Gene Lab Corp (“the Company”) their desire to resign from their positions at the Company.
Appointed

Sook Keng Yeoh

Chief Executive Officer
BGLC · BioNexus Gene Lab Corp
Effective
2022-08-09
Filed
August 15, 2022, 7:59 PM ET
On August 9, 2022, the Board of Directors of the Company approved the appointments of Mr. Yeat Min Fong as the Chairman and director, Mr. Sook Keng Yeoh as the Chief Executive Officer and director, and Ms. Yee Meng Wong as the President and director, effective August 9, 2022.
Appointed

Yeat Min Fong

Chairman
BGLC · BioNexus Gene Lab Corp
Effective
2022-08-09
Filed
August 15, 2022, 7:59 PM ET
On August 9, 2022, the Board of Directors of the Company approved the appointments of Mr. Yeat Min Fong as the Chairman and director, Mr. Sook Keng Yeoh as the Chief Executive Officer and director, and Ms. Yee Meng Wong as the President and director, effective August 9, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Soo Kow Lai resigned as Chairman at BioNexus Gene Lab Corp.

Action
resigned
Role
Chairman
Exact text from the filing
On August 9, 2022, Mr. Soo Kow Lai, the Chairman and director, Mr. Chan Chong Wong, the Chief Executive Officer and director, and Mr. Chi Yuen Leong, the President and director, notified Bionexus Gene Lab Corp (“the Company”) their desire to resign from their positions at the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Yee Meng Wong was appointed as President at BioNexus Gene Lab Corp.

Action
appointed
Role
President
Exact text from the filing
On August 9, 2022, the Board of Directors of the Company approved the appointments of Mr. Yeat Min Fong as the Chairman and director, Mr. Sook Keng Yeoh as the Chief Executive Officer and director, and Ms. Yee Meng Wong as the President and director, effective August 9, 2022.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Chan Chong Wong resigned as Chief Executive Officer at BioNexus Gene Lab Corp.

Action
resigned
Role
Chief Executive Officer
Exact text from the filing
On August 9, 2022, Mr. Soo Kow Lai, the Chairman and director, Mr. Chan Chong Wong, the Chief Executive Officer and director, and Mr. Chi Yuen Leong, the President and director, notified Bionexus Gene Lab Corp (“the Company”) their desire to resign from their positions at the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Chi Yuen Leong resigned as President at BioNexus Gene Lab Corp.

Action
resigned
Role
President
Exact text from the filing
On August 9, 2022, Mr. Soo Kow Lai, the Chairman and director, Mr. Chan Chong Wong, the Chief Executive Officer and director, and Mr. Chi Yuen Leong, the President and director, notified Bionexus Gene Lab Corp (“the Company”) their desire to resign from their positions at the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Sook Keng Yeoh was appointed as Chief Executive Officer at BioNexus Gene Lab Corp.

Action
appointed
Role
Chief Executive Officer
Exact text from the filing
On August 9, 2022, the Board of Directors of the Company approved the appointments of Mr. Yeat Min Fong as the Chairman and director, Mr. Sook Keng Yeoh as the Chief Executive Officer and director, and Ms. Yee Meng Wong as the President and director, effective August 9, 2022.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Yeat Min Fong was appointed as Chairman at BioNexus Gene Lab Corp.

Action
appointed
Role
Chairman
Exact text from the filing
On August 9, 2022, the Board of Directors of the Company approved the appointments of Mr. Yeat Min Fong as the Chairman and director, Mr. Sook Keng Yeoh as the Chief Executive Officer and director, and Ms. Yee Meng Wong as the President and director, effective August 9, 2022.
View on SEC.gov

BioNexus Gene Lab Corp filing history →

Source: SEC EDGAR
accession 0001477932-22-006086
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.